$77 Million

Nivalis Therapeutics

Initial Public Offering

Lead Left Bookrunner, June 2015

Alpine Immune Sciences Inc is engaged in discovering and developing modern, protein-based immunotherapies targeting the immune synapse to treat cancer, inflammation, and other diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics potentially capable of modulating human immune system proteins.